Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
114M
-
Number of holders
-
162
-
Total 13F shares, excl. options
-
95.7M
-
Shares change
-
-11.8M
-
Total reported value, excl. options
-
$203M
-
Value change
-
-$40.8M
-
Put/Call ratio
-
9.78
-
Number of buys
-
79
-
Number of sells
-
-84
-
Price
-
$2.12
Significant Holders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) as of Q3 2023
205 filings reported holding FATE - FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share as of Q3 2023.
FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) has 162 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 95.7M shares
of 114M outstanding shares and own 83.66% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (13.1M shares), BlackRock Inc. (12.5M shares), VANGUARD GROUP INC (10.9M shares), Bellevue Group AG (4.85M shares), D. E. Shaw & Co., Inc. (4.71M shares), JOHNSON & JOHNSON (3.38M shares), JPMORGAN CHASE & CO (2.6M shares), FEDERATED HERMES, INC. (2.45M shares), JACOBS LEVY EQUITY MANAGEMENT, INC (2.39M shares), and STATE STREET CORP (2.27M shares).
This table shows the top 162 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.